Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 133 | 12,174 | 45% |
| 2020 | 135 | 11,487 | 51% |
| 2021 |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 20% of the cases CMS names in Michigan; 104 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
CGM & insulin pump management in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Illinois
| 2025 est. |
| ≈ 24,900 |
| – |
| 2026 est. | ≈ 27,100 | – |
| 156 |
| 15,132 |
| 55% |
| 2022 | 173 | 17,677 | 59% |
| 2023 | 189 | 20,203 | 63% |
| 2024 | 215 | 22,586 | 66% |
| 2025 from claims | – | 24,931 22,880–26,377 | 67% |
| 2026 forecast | – | 27,114 23,856–31,288 | 67% |
| 2027 forecast | – | 29,177 24,943–34,770 | 68% |
| 2028 forecast | – | 31,379 26,183–38,423 | 69% |
| 2029 forecast | – | 33,727 27,547–42,297 | 70% |
| 2030 forecast | – | 36,229 29,024–46,427 | 70% |
In 2025, 32% hospital outpatient, 68% office. The share outside the hospital has moved −8 pts since 2019.
| 30,536+34%/yr |
| +34%/yr |
| 27.1 |
| 66% |
| 55,500 in 2030+10%/yr |
| Indiana | 163 | 22,848+22%/yr | +22%/yr | 31.9 | 89% | 37,600 in 2030+8.6%/yr |
| Missouri | 161 | 21,566+29%/yr | +29%/yr | 34.1 | 80% | 38,800 in 2030+10%/yr |
| Kansas | 76 | 13,034+33%/yr | +33%/yr | 31.9 | 84% | 23,200 in 2030+10%/yr |
| Wisconsin | 144 | 12,963+33%/yr | +33%/yr | 22.5 | 71% | 25,100 in 2030+12%/yr |
| Minnesota | 116 | 12,114+19%/yr | +19%/yr | 26.2 | 80% | 25,600 in 2030+13%/yr |
| Iowa | 54 | 9,706+30%/yr | +30%/yr | 21.6 | 65% | 17,100 in 2030+9.9%/yr |
| Nebraska | 54 | 8,132+36%/yr | +36%/yr | 30.9 | 76% | 14,300 in 2030+9.9%/yr |
| South Dakota | 26 | 3,993+45%/yr | +45%/yr | 30.4 | 9% | 7,150 in 2030+10%/yr |
| North Dakota | 12 | 1,926+24%/yr | +24%/yr | 19.1 | 48% | 3,400 in 2030+9.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 30% of company spending on these surgeons in 2025, level with 2024.
In 2025, 9 companies reported engagement with Michigan’s surgeons worth $428K in consulting, speaking, meals and travel tied to these products, about $1,990 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.